PDI guided lower for the third quarter and full year, but CEO Nancy Lurker, says now is the time for investors to look at the company as it just made its first acquisition in the molecular diagnostic space, which has the potential for more growth and higher margins than PDI’s traditional core business and she is bullish on where the new vertical will take the company. Lurker believes the diagnostic business is indicative of what we see happening in healthcare overall with the explosion of personalized healthcare and genomics. Earlier diagnosis of disease will ultimately save the healthcare system more money and impact patient care more positively.

More from Video

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

3M's Chief Science Advocate on Advancing Healthcare, Autos and Young Scientists

3M's Chief Science Advocate on Advancing Healthcare, Autos and Young Scientists

Listen: Should You Buy Cisco Now?

Listen: Should You Buy Cisco Now?

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

It's Dumb to Think There Aren't Already Monopolies in Big Tech

It's Dumb to Think There Aren't Already Monopolies in Big Tech